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Background: Randomized clinical trials (RCTs) are the preferred source of evidence to support 2 
professional societies’ guidelines. The Fragility Index (FI), defined as the minimum number of 3 
patients whose status would need to switch from non-event to event to render a statistically 4 
significant result non-significant, quantitatively estimates the robustness of RCTs results. We 5 
evaluate RCTs supporting current guidelines on myocardial revascularization using the FI and FI 6 
minus number of patients lost to follow-up (FI-LTF). 7 
Methods and results: The FI and FI-LTF of RCTs supporting the 2012 American College of 8 
Cardiology(ACC)/American Heart Association(AHA) Guideline for the Diagnosis and 9 
Management of Patients with Stable Ischemic Heart Disease, the 2014 Focused Update of the 10 
ACC/AHA Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart 11 
Disease, and the 2018 European Society of Cardiology/European Association for Cardio-12 
Thoracic Surgery Guidelines for Myocardial Revascularization were calculated. Of 414 RCTs 13 
identified, 160 were eligible for FI calculation. The median FI was 8.0 (95%confidence 14 
interval(CI) 5.0-9.0) and the median FI-LTF was 1.0 (95%CI 0.0-3.0). FI was ≤3, indicating very 15 
limited robustness, in 44(27.5%) RCTs, and was lower than the number LTF, indicating limited 16 
robustness, in 68(42.5%) RCTs. FI was significantly (all p<0.05) correlated with the sample size, 17 
number of events, statistical power, journal impact factor, use of intention-to-treat analysis and of 18 
composite endpoints, and negatively correlated with the use of percutaneous interventions in the 19 
treatment arm and the p-value level. 20 
Conclusion: More than a quarter of RCTs that support current guidelines on myocardial 21 




number of patients lost to follow-up. These findings suggest that the robustness of the findings 1 
that support current myocardial revascularization guidelines is tenuous and vulnerable to change 2 





Randomized controlled trials (RCTs) are considered the gold standard to compare two or more 2 
treatments. Randomization aims to minimize (and ideally eliminate) the effect of known, 3 
unmeasured or unknown confounders and is traditionally accepted to be able to provide a reliable 4 
estimate of whether or not a treatment has an effect (or a larger effect than another). 5 
RCTs are the preferred source of evidence in guidelines and professional societies or expert 6 
position papers. They are the foundations of evidence-based medicine, and influence the clinical 7 
decision-making of the great majority of physicians and affect the outcomes of most of our 8 
patients. 9 
The statistical significance of the results of RCTs is generally evaluated using a fixed threshold 10 
of metrics, such as the p-value of the confidence interval. However, this approach has been 11 
repeatedly criticized by authors and statistical associations in the recent past.1,2 Indeed, the p- 12 
value is fraught with all the limitations inherent to a frequentist statistical framework, which 13 
include null hypothesis testing, inability to incorporate prior knowledge, risk of being 14 
misinterpreted as proof of evidence or direct probability statement, occasional internal logical 15 
inconsistency, accurate estimation only based on large samples, and reliance on approximation 16 
for many computational models. In addition, the p-value does not provide any direct information 17 
on the existence of a true treatment effect and, according to many, is a simplistic solution to the 18 
complexities of probability theory.3 P-value-based statistical significance is also heavily affected 19 
by methodological limitations and can be lost (or gained) by a shift of few events in one group. 20 
To partially overcome these limitations and to provide an objective estimate of the solidity of 21 




number of patients whose status would need to switch from non-event to event to render a 1 
significant result non-significant. The lower the value of FI, the lower the solidity and 2 
robustness of the results.4,5 Whilst FI is still dependent on the p-value and the problems 3 
associated with choosing an arbitrary threshold, it adds additional information as a form of 4 
sensitivity analysis which combines the sample size and the precision of the point estimate. 5 
Accordingly, FI offers a way to “stress-test” any study p-values, offering a pragmatic and 6 
poignant sensitivity measure and it evidently proves less focus of dichomotous testing in 7 
itself, but actually weighs it in light of sample size and events accrued. The FI may provide 8 
an additional perspective informing practitioners on the robustness of the findings of a RCT 9 
analyzed according to a frequentist framework and reporting p-values. Bayesian approaches 10 
may provide a better alternative to counter the problems associated with frequentist analyses 11 
of randomized trials.  12 
Cardiovascular disease affects more than 85 million of people in the US only.6 Current 13 
guidelines on myocardial revascularization potentially affect the lives of millions of patients 14 
worldwide. 15 
In this report, we evaluate the solidity of the evidence supporting the current US and 16 





Selection of randomized controlled trials 2 
We identified all RCTs cited in the 2012 American College of Cardiology (ACC)/American 3 
Heart Association (AHA) Guideline for the Diagnosis and Management of Patients with Stable 4 
Ischemic Heart Disease,7 the 2014 Focused Update of the ACC/AHA Guideline for the Diagnosis 5 
and Management of Patients with Stable Ischemic Heart Disease,8 and the 2018 European Society 6 
of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for 7 
Myocardial Revascularization.9 All trials were independently reviewed by two reviewers (I.H. 8 
and M.R.) and were included for analysis and data extraction if they reported at least one 9 
statistically significant dichotomous primary or secondary outcome (P < 0.05 or a 95% 10 
confidence interval (95%CI) that excluded the null value). For trials reporting multiple significant 11 
primary and/or secondary outcomes, data were extracted for the primary and/or secondary 12 
outcome with the lowest p-value. The data that support the findings of this study are available 13 
from the corresponding author upon reasonable request. 14 
Data extraction 15 
For each RCT, the following data were recorded: citation in European or American guideline, 16 
journal of publication and impact factor (according to Thomson Reuters-Clarivate Analytics), year 17 
of publication, use or surgical, medical or percutaneous intervention in treatment arm, single- or 18 
multi-center study, geographical locations of the participating centers, class of recommendation 19 
(COR) and level of evidence (LOE) supported. Details of the primary or secondary outcome 20 
(definition of outcome, composite or non-composite endpoints) sample size, number of events, 21 




for the primary outcome, number of patients lost to follow-up (LTF), and number of crossovers 1 
were also collected. Two reviewers (I.H. and M.R.) independently extracted data from the included 2 
trials and the first author (M.G.) resolved any discrepancy. 3 
Calculation of Fragility Index 4 
FI for the statistically significant primary or secondary outcomes were calculated as described by 5 
Walsh et al.5 The results for each outcome were entered in a 2x2 contingency table following 6 
which the p-value for each outcome was calculated using the two-sided Fisher’s exact test. 7 
Single participants were iteratively shifted one at a time in the lower-incidence treatment group 8 
from “non-event” to “event” and the p-value for the 2x2 table re-calculated. The FI for an 9 
outcome equalled the smallest number of participants required to turn the re-calculated p-value 10 
non-significant (≥0.05). 11 
Calculation of Fragility Index minus lost to follow-up 12 
FI minus LTF were calculated following the methods used by Mazzinari et al.10 as the difference 13 
between the fragility index and number of patients lost to follow-up. 14 
Statistical analysis 15 
Continuous variables were reported as medians with their first-third quartile, whereas categorical 16 
variables were reported as counts and percentages. 17 
A visual inspection of the data showed that FI and FI-LTF were non-normally distributed, 18 
therefore non-parametric methods were used to compare the groups. The Mann-Whitney U test 19 




groups. To assess the interaction between two categorical variables with respect to FI/FI-LTF, the 1 
Scheirer-Ray-Hare test was used. Categorical variables were compared using Fisher’s exact test. 2 
Correlations between FI, FI-LTF and different variables were calculated using Spearman’s 3 
correlation coefficient for continuous variables and Rank-Biserial correlation coefficient for 4 
dichotomous variables. A local regression (LOESS) curve was used to explore the relationship 5 
between the variables. 6 
Multivariable linear regression with a quasi-poisson distribution was used to explore for 7 
independent predictors of FI and FL-LTF, with an exploratory and hypothesis-generating scope. 8 
Results are reported as regression coefficient (β) and 95%CI. 95%CIs were calculated using 9 
percentile bootstrapping with 1000 samples. Two-sided significance testing was used and a p-10 
value < 0.05 was considered significant. All analyses were performed using SPSS version 22 11 






Selection of randomized controlled trials and data analysis 2 
A total of 414 RCTs were identified: 171 in the ACC/AHA guidelines, and 243 in the ESC/EACTS 3 
guidelines. 281 RCTs reported dichotomous outcomes, of which 167 (64 in the ACC/AHA guidelines and 4 
103 in the ESC/EACTS guidelines) reported at least one statistically significant primary or secondary 5 
outcome (125 primary, 35 secondary). Seven RCTs were quoted in both ACC/AHA and ESC/EACTS 6 
guidelines, and were thus entered only once to avoid duplication, leaving 160 RCTs for the analyses 7 
(Figure 1, Supplementary Table 1). Thirty-three RCTs (20.6%) were published prior to the year 2000, 69 8 
(43.1%) from 2000 to 2010, and 58 (36.3%) after 2010. 9 
There were 143 (90.5%) multi-center RCTs, and 78 (48.8%) originated from Europe. The 10 
median sample size was 1192 (379, 2672). The details of the RCTs and endpoints are 11 
summarized in Table 1. 12 
Details of CORs, LOEs, and numbers of RCTs for the individual guidelines are 13 
summarized in Table 2. There were a total of 396 recommendations (161 ACC/AHA, 235 14 
ESC/EACTS) supported by 375 RCTs (151 ACC/AHA, 224 ESC/EACTS): 168 Class I 15 
recommendations supported by 168 RCTs; 120 Class IIa recommendations supported by 16 
80 RCTs; 66 Class IIb recommendations supported by 63 RCTs; and 42 Class III 17 
recommendations supported by 64 RCTs. 18 
Of these recommendations, 75 were designated LOE A with 178 RCTs; 154 LOE B with 19 
172 RCTs; and 167 LOE C with 25 RCTs. 20 




The distribution of FI, losses to follow-up, and FI – LTF are shown in Figure 2. 1 
The median FI for all the 160 trials analyzed was 8.0 (95%CI 5.0-9.0; IQR 3.0, 15.0): 10.0 (95%CI 2 
8.0-16.0; IQR 4.0, 21.0) for ACC/AHA guidelines, and 5.0 (95%CI 4.0-8.0; IQR 2.0, 13.5) for 3 
ESC/EACTS guidelines (p = 0.02). FI was ≤ 3 for 44 RCTs (27.5%): 12 (18.8%) in the 4 
ACC/AHA, and 34 (33.0%): in the ESC/EACTS guidelines (p = 0.07) (Table 3).  5 
For primary endpoints, the overall median FI was 8.5 (IQR 4.0, 16.3): 12.0 (IQR 5.0, 21.0) for 6 
ACC/AHA, and 7.0 (IQR 3.0, 15.0) for ESC/EACTS guidelines (p = 0.04). For secondary 7 
endpoints, the median FI was 4.0 (IQR 2.0, 9.0): 7.0 (IQR 4.0, 22.0) for ACC/AHA, and 3.5 (IQR 8 
1.0, 7.0) for ESC/EACTS guidelines (p = 0.07) (Table 3). 9 
There was no statistically significant difference in FI for era of publication (p=0.66) (Table 4), 10 
although the median FI was progressively lower for RCTs published in the later study years when 11 
considering the eras prior to 2000, from 2000 to 2010, and after 2010. 12 
There was no difference in the median FI of RCTs used to support different CORs (p=0.25) and 13 
LOEs (p=0.16) (Table 4).  14 
The FI of RCTs involving surgery in the treatment arm was not significantly different from that of 15 
non-surgical RCTs (p=0.59). RCTs involving percutaneous-intervention in the treatment arm had a 16 
significantly lower FI than non-percutaneous intervention RCTs (p<0.01).  17 
RCTs with composite endpoints had a significantly higher FI than RCTs with single endpoints 18 




Details of FI-LTF are given in Table 3. The overall median FI – LTF was 1.0 (95% CI 0.0-3.0; 1 
IQR 0.0, 9.0): 3.0 (95% CI 0.0-7.0; IQR 0.0, 13.0) for ACC/AHA, and 1.0 (95% CI 0.0-3.0; 2 
IQR 0.0, 7.5) for ESC/EACTS guidelines (p = 0.45). 3 
FI was lower than the number of patients LTF in 68 (42.5%) RCTs: 28 (43.8%) in ACC/AHA, 4 
and 45 (43.7%) RCTs in ESC/EACTs guidelines (p = 1.00) (Table 3 and Figure 2). 5 
Correlation between fragility index, fragility index minus number lost to follow-up and 6 
trial characteristics 7 
The FI was significantly correlated with the sample size (Spearman correlation (R) = 0.35, 8 
p<0.001), number of events (R=0.60, p<0.001), statistical power (R=0.21, p=0.02), impact 9 
factor of journal of publication (R=0.34, p<0.001), use of intention to treat analysis (R=0.20, 10 
p=0.01) and of composite endpoints (R=0.17, p=0.03). FI was negatively correlated with use 11 
of percutaneous intervention in the treatment arm (R=-0.25, p=0.001), the p-value level (R=-12 
0.63, p<0.001) and was lower for primary endpoints (R=-0.18, p=0.02) (Figure 3, 13 
Supplementary Table 2). 14 
The FI – LTF was negatively correlated with the p-value level (R=-0.42, p<0.001) and the 15 
number of patients lost to follow-up (R=-0.65, p<0.001) (Supplementary Table 2). 16 
Multiple regression revealed that sample size, number of events, and p-value level were 17 
independent predictors of FI (p < 0.01), while sample size, number of events, number lost to 18 






We have found that the RCTs supporting the current guidelines on myocardial 2 
revascularizationare generally fragile. The median FI was 8, meaning that a shift of 8 patients 3 
from non-event to event would have significantly changed the results of the original analysis. Of 4 
note, 27.5% of the RCTs had a FI ≤ 3, and even the median FI of RCTs used to support class I 5 
LOE A recommendations (considered the most solid in clinical medicine) was below 10. Even 6 
more concerning, the median FI-LTF was 1 and 42.5% of RCTs had a negative FI – LTF value, 7 
indicating that their FI was smaller than their number of patients who were lost to follow-up. 8 
Despite the common critiques of surgical RCTs, trials evaluating surgical interventions had FI 9 
similar to non-surgical trials. In contrast, trials aimed at evaluating percutaneous treatment had 10 
significantly lower FI. 11 
Confirming previous reports,10 the sample size and the impact factor of the journal of publication 12 
were significantly correlated with the FI. The number of events, statistical power of the trial, p- 13 
value level, use of composite endpoints and intention to treat analysis were also correlated with 14 
the FI. Similar to previous findings in other fields,11,12 the treatment effect size was not correlated 15 
with the FI. 16 
Interestingly, the FI decreased (although not significantly) over time, with most recent RCTs 17 
having lower FI. This may be related to the increasing difficulty in finding support for large 18 
RCTs, and may elicit concerns regarding enacted policy changes that may have been based on 19 
fragile evidence.  20 




value (usually 0.05). The p-value level is influenced by methodological factors and may vary 1 
substantially with shifting of only few events from one group to the other. In fact, the use of the 2 
p-value approach has been heavily criticized in recent years. The American Statistical 3 
Association, in a Statement of Statistical Significance and P-Value, has summarized the many 4 
issues related to the use of boundary p-values.2 Reliance on a fixed p-value level has also been 5 
identified as one of the possible cause of the low level of replication rate in current scientific 6 
research.  7 
The FI was introduced in 1990 with the aim of complementing the p-value and providing an 8 
intuitive measure of the solidity of the results of an RCT.4 The FI is the number of participants 9 
that need to switch from non-event to event in the lower incidence treatment group for a trial to 10 
lose statistical significance.5 In a rather misnomer fashion, a lower FI value indicates lower 11 
solidity of the results. An additional important measure is the FI minus the number of patients 12 
LTF, as one can make the case that the outcome of patients LTF could have changed the 13 
statistical results of the trial. This is particularly relevant when the likelihood of occurrence of 14 
the outcome may be the reason for the LTF.13 To date no defined FI boundaries exist for the 15 
definition of “frail” RCTs. Intuitively the FI must be correlated with the sample size, treatment 16 
effect, power and existing evidence, and the FI threshold may vary from case to case. 17 
Walsh et al found that among 399 RCTs published in high-impact medical journals between 2004 18 
and 2010, the median FI was 8 and that 25% of them had a FI ≤3. Notably, in 53% of the trials, 19 
the FI was lower than the number of patients LTF.5 Docherty and colleagues, in a review of the 20 
RCTs supporting the guidelines for the management of patients with chronic heart failure, had 21 
more reassuring results with a median FI of 26, 35% of the trials with a FI ≤10 and 20% with FI 22 




In general, the strength of the published RCTs in different fields has been reported to be low. In a 1 
review of the RCTs quoted in the 2016 Chest Guidelines and Expert Recommendations for 2 
Venous Thrombo-embolism, the median FI was 5 (median sample size 400), while a similar 3 
review of the 2017 guidelines for the treatment of diabetes reported a median FI of 16 (median 4 
sample size 2548). Low or very low FI have been reported in trauma (median FI 3, median sample 5 
size 207), critical care (median FI 2, median sample size 126.5), nephrology (median FI 3, median 6 
sample size 134), spine and sport surgery (median FI 2 for both, median sample size 132 and 64, 7 
respectively), and anesthesiology (median FI 4, median sample size 150).12,14–20 8 
It is important to note that there are ethical reasons to design RCT’s sample size to produce the 9 
required level of evidence using the minimum number of participants. In fact, while enrolling a 10 
larger number of participants may produce stronger evidence against the null, this implies 11 
randomizing patients when some level of evidence could be already generated from the available 12 
data, and may be seen as violating the equipoise principle. On the other hand, fragile results that 13 
are contradicted by subsequent studies or require confirmation in other trials may also be 14 
potentially harmful to patients and elicit equally important ethical questions. The delicate balance 15 
between the number of patients whose treatment is based on randomization and the solidity of the 16 
achieved results is the basis of RCT’s sample size calculation. 17 
Our findings and similar ones from other medical and surgical specialties highlight the need, 18 
whenever using an RCT to inform practice guidelines, to carefully consider, on top of clinical 19 
and statistical significance, the actual robustness of the results and the consequent role of play of 20 
chance in guiding its conclusions. We suggest that future practice guidelines provide detailed 21 
reports of RCTs fragility, and that fragility should be considered when planning pivotal and 22 




patients, clinicians, and stakeholders. 1 
Several limitations of this analysis need to be considered. The FI, like the p-value, should not be 2 
interpreted as a measure of the effect, but only of the fragility of the results of a trial. In addition, 3 
the FI does not per se overcome the limitation of a frequentist framework, but simply provides an 4 
additional perspective on a study weaknesses. There are no established boundaries to define an 5 
RCT outcome as robust or fragile and the same FI can have different meanings in different 6 
clinical contexts. It is also plausible that the FI of primary outcomes consisting of hard endpoints, 7 
such as mortality, may warrant a different interpretation than those involving functional 8 
measures. As trials are usually powered for the primary outcome, calculation of the FI for 9 
secondary outcomes, which should only be considered hypothesis- generating, must be viewed 10 
with skepticism. FI, p-values, events and sample are mathematically related and thus their 11 
multivariable analysis is limited by collinearity and clustering features, with eventual results 12 
mainly exploratory and hypothesis-generating. Finally, the FI can be applied only to trials with a 13 
positive result and a dichotomous outcomes and its calculation convert time-to- event into 14 
dichotomous outcomes. Consequently, only 160 RCTs were eligible for analysis and the 15 
generalizability of our results may be limited. 16 
In conclusion, we have found that the solidity of the RCTs used to support the current guidelines 17 
on myocardial revascularization is low and seems to be decreasing in the most recent years. Our 18 
data support the need for large RCTs addressing important clinical questions with adequate trial 19 
design, power and sample size. Our findings also suggest that metrics related to FI of the 20 
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FIGURE LEGENDS 1 
Figure 1. Flowchart of the selection process of randomized controlled trials (RCTs). 2 
Figure 2. Frequencies of (A) fragility indices; (B) fragility indices minus patient number lost to 3 
follow-up; and (C) patient numbers lost to follow-up in all trials (n=160). 4 
Figure 3. (A) Correlation between fragility index and total sample size (Spearman correlation (R) 5 
= 0.35, P<0.001); and (B) correlation between fragility index and number of outcomes (Spearman 6 
R = 0.60, P<0.001). Black line represents fitted local regression (LOESS) curve, dark gray area 7 




Table 1: Characteristics of randomized controlled trials quoted in the guidelines. 1 
ALL TRIALS ¶ AHA /ACC GUIDELINES ESC/EACTS GUIDELINES P-VALUE ‡ 2 
 3 
Number 160 64 103  
Year of publication (< 2000) 33 (20.6) 31 (49.2) 2 (2.1) <0.001 
Year of publication (2000 – 2010) 69 (43.1) 29 (46.0) 40 (41.2)  
Year of publication (>2010) 58 (36.3) 3 (4.8) 55 (56.7)  
Primary/secondary endpoint (%) 125/35 (78.1/21.9) 53/11 (82.8/17.2) 79/24 (76.7/23.3) 0.44 
Composite primary endpoint 81 (50.9) 32 (50.8) 54 (52.4) 0.87 
Composite secondary endpoint 9 (5.6) 4 (6.2) 5 (4.9) 0.73 
Sample size 1192.0 [378.8, 2671.5] 1805.0 [562.5, 4033.0] 888.0 [337.0, 2157.0] 0.02 
Number of intervention patients 594.0 [191.3, 1291.3] 905.5 [281.3, 2012.0] 442.0 [180.5, 1061.5] 0.02 
Number of control patients 598.0 [191.0, 1275.3] 903.0 [281.3, 2021.0] 438.0 [178.5, 1081.0] 0.02 
% Power 80.0 [80.0, 90.0] 85.0 [80.0, 90.0] 80.0 [80.0, 90.0] 0.03 
Number of events in intervention patients 53.0 [19.8, 158.3] 108.5 [34.3, 275.5] 38.0 [16.5, 103.0] <0.01 
Number of events in control patients 66.0 [20.0, 187.3] 150.0 [25.3, 262.5] 52.0 [17.5, 112.5] 0.001 
Number of patients lost to follow-Up 6.5 [0.0, 40.3] 15.5 [0.3, 63.0] 5.0 [0.0, 38.0] 0.07 
% Crossover 4.2 [1.9, 8.0] 5.19 [2.4, 8.3] 4.2 [1.8, 8.0] 0.75 
Surgery trials (%) 123 (76.9) 42 (65.6) 83 (80.6) 0.04 
Percutaneous intervention trials (%) 70 (43.8) 43 (67.2) 28 (27.2) <0.001 
Medical treatment trials (%) 83 (51.9) 20 (31.2) 66 (64.1) <0.001 
Location 0.05 
 Asia 9 (5.6) 1 (1.6) 9 (8.7)  
 Europe 78 (48.8) 30 (46.9) 51 (49.5)  
 North america 25 (15.6) 14 (21.9) 12 (11.7)  
 South america 2 (1.2) 2 (3.1) 0 (0.0)  
 Multi-continental 46 (28.7) 17 (26.6) 31 (30.1)  
Single/multi-center trials (%) 15/143 (9.5/90.5) 7/56 (11.1/88.9) 8/94 (7.8/92.2) 0.58 
Intention to treat analysis (%) 0.03 
 Yes 140 (88.1) 61 (96.8) 86 (83.5)  
 No 16 (10.1) 2 (3.2) 14 (13.6)  
 Not reported 3 (1.9) 0 (0.0) 3 (2.9)  
P-value (%) 0.10 
 0.01-0.001 38 (23.8) 18 (28.1) 23 (22.3)  
 0.05-0.01 78 (48.8) 24 (37.5) 56 (54.4)  





¶ Total after exclusion of 7 duplicate trials 1 
*Numbers reported as median [IQR] or total (%). 2 




Table 2. Number of randomized trials supporting different classes of recommendations and levels of evidence. 1 
 2 





RCTs = 375 CORs = 161 RCTs = 151 CORs = 235 RCTs = 224 
Class I 168 (42.4) 168 (44.8) 58 (36.0) 44 (29.1) 110 (46.8) 124 (55.4) 
Class IIa 120 (30.3) 80 (21.3) 47 (29.2) 39 (25.8) 73 (31.1) 41 (18.3) 
Class IIb 66 (26.7) 63 (16.8) 29 (18.0) 36 (23.9) 37 (15.7) 27 (12.1) 




RCTs = 375 LOEs = 161 RCTs = 151 LOEs = 235 RCTs = 224 
LOE A 75 (18.9) 178 (47.5) 14 (8.7) 30 (19.9) 61 (26.0) 148 (66.1) 
LOE B 154 (38.9) 172 (45.9) 78 (48.4) 102 (67.5) 76 (32.3) 70(31.3) 
LOE C 167 (42.2) 25 (6.6) 69 (42.9) 19 (12.6) 98 (41.7) 6 (2.6) 




Table 3. Fragility Index. P-values were calculated using Mann-Whitney and Fisher’s exact tests for continuous and categotical 1 
variables respectively. The Scheirer-Ray-Hare test was used to determine p-values for non-parametric interactions. 2 






P-Value ‡ 9 
Fragility index 8.0 [3.0, 15.0] 10.0 [4.0, 21.0] 5.0 [2.0, 13.5] 0.02 
Fragility index minus number lost to follow-up 
(FI – LTF) 
1.0 [0.0, 9.0] 3.0 [0.0, 13.0] 1.0 [0.0, 7.5] 0.45 
Fragility index ≤ 3 (%) 44 (27.5) 12 (18.8) 34 (33.0) 0.05 
Fragility index < LTF (%) 68 (42.5) 28 (43.8) 45 (43.7) 1.00 
  
Fragility index by year of publication 0.22¶ 
<2000 10.0 [4.0, 20.0] 10.0 [3.5, 20.5] 7.5 [5.8, 9.3] 0.73 
2000 – 2010 8.0 [3.8, 16.0] 9.5 [5.0, 21.0] 4.5 [2.8, 12.3] 0.04 
>2010 7.0 [2.0, 14.8] 33.0 [33.0, 43.5] 6.0 [2.0, 12.0] 0.01 
  
Primary endpoints  
 Number of endpoints 125 52 73  
 Fragility index 8.5 [4.0, 16.3] 12.0 [5.0, 21.0] 7.0 [3.0, 15.0] 0.04 
 Fragility index minus number lost to 
follow-up (FI – LTF) 
1.0 [0.0, 10.0] 0.0 [0.0, 13.0] 1.0 [0.0, 8.0] 0.72 
  
Secondary endpoints  
 Number of endpoints 35 11 24  
 Fragility index 4.0 [2.0, 9.0] 7.0 [4.0, 22.0] 3.5 [1.0, 7.0] 0.07 
 Fragility index minus number lost to 
follow-up (FI – LTF) 
2.0 [0.0, 8.0] 4.0 [1.5, 18.5] 1.0 [0.0, 5.5] 0.19 
*Numbers reported as median [IQR] or total (%). 10 
‡ P-values calculated using Mann-Whitney and Fisher’s exact tests for continuous and categotical variables respectively. 11 




Table 4. Fragility index (FI) of randomized controlled trials by classes of recommendations, levels of evidence, and years of 1 
publication. P- values were calculated using Kruskal Wallis test. 2 





I 43 9.0 [4.0, 26.0] 3.0 [0.0, 12.5] 
IIa 16 6.0 [3.8, 12.0] 3.0 [0.0, 8.5] 
IIb 12 9.0 [1.8, 15.3] 0.0 [0.0, 6.5] 
III 7 5.0 [3.5, 6.5] 0.0 [0.0, 0.0] 
P-value  0.25 0.14 
Level of evidence  
A 54 8.5 [4.0, 23.0] 2.0 [0.0, 12.0] 
B 22 5.0 [3.0, 10.8] 1.0 [0.0, 6.8] 
C 2 9.0 [5.0, 13.0] 0.0 [0.0, 0.0] 
P-value  0.16 0.28 
Year of publication  
<2000 33 10.0 [4.0, 20.0] 3.00 [0.00, 11.00] 
2000 – 2010 69 8.0 [3.8, 16.0] 3.00 [0.00, 9.25] 
>2010 58 7.0 [2.0, 14.8] 0.00 [0.00, 6.75] 
P-value  0.66 0.18 




Table 5. Comparisons of fragility indices (FI) of different categories of randomized controlled trials (RCTs). P-values were calculated 1 
using Mann-Whitney test 2 
 3 
 4 
Comparison FI P-value 
 
Surgery vs non-surgery RCTs 
 
7.0 [3.0, 20.0] vs 8.0 [3.0, 15.0] 
 
0.59 
Surgery vs Percutaneous intervention 
RCTs (n=102) ¶ 
 
7.0 [3.0, 20.0] vs 4.0 [2.0, 10.0] 
 
0.06 
Surgery vs medical treatment RCTs 
(n=110) ¶¶ 
7.0 [3.0, 20.0] vs 9.0 [4.0, 19.5]  
0.59 
Percutaneous intervention vs non- 
percutaneous intervention RCTs 
 
5.0 [2.0, 12.0] vs 11.0 [5.0, 21.0] 
 
<0.01 
Percutaneous intervention vs medical 
treatment RCTs (n=147) ‡ 




Composite vs non-composite endpoints 
 




¶ Trials with percutaneous intervention and surgery as their treatment arms were categorized as surgery trials. 6 
¶¶ Trials with surgery and medical treatment as their treatment arms were categorized as surgery trials. 7 
‡ Trials with percutaneous intervention and medical treatment as their treatment arms were categorized as percutaneous intervention trials. 8 
